Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Dicuonzo

Showing results (21-30 of 23) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 23 results.
Medical Microbiology and Immunology|February 6, 2002
Enterococcus spp. produces slime and survives in rat peritoneal macrophagesL Baldassarri, R Cecchini, L Bertuccini, et al.
Clinical and Experimental Immunology|October 2, 2008
Toll-like receptor 4 Asp299Gly and Thr399Ile polymorphisms in gastric cancer of intestinal and diffuse histotypesD Santini, S Angeletti, A Ruzzo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 1, 2010
Early magnesium modifications as a surrogate marker of efficacy of cetuximab-based anticancer treatment in KRAS wild-type advanced colorectal cancer patientsB Vincenzi, S Galluzzo, D Santini, et al.
Pageof 3

Showing results (21-30 of 23) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 23 results.
Medical Microbiology and Immunology|February 6, 2002
Enterococcus spp. produces slime and survives in rat peritoneal macrophagesL Baldassarri, R Cecchini, L Bertuccini, et al.
Clinical and Experimental Immunology|October 2, 2008
Toll-like receptor 4 Asp299Gly and Thr399Ile polymorphisms in gastric cancer of intestinal and diffuse histotypesD Santini, S Angeletti, A Ruzzo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 1, 2010
Early magnesium modifications as a surrogate marker of efficacy of cetuximab-based anticancer treatment in KRAS wild-type advanced colorectal cancer patientsB Vincenzi, S Galluzzo, D Santini, et al.
Pageof 3